文献速递心血管外周血管US

华法林使用与冠状动脉钙化进展相关:来自系列血管内超声的见解

Warfarin Use Is Associated With Progressive Coronary Arterial Calcification: Insights From Serial Intravascular Ultrasound.
PubMed 文献 · JACC Cardiovasc Imaging · 2017-07-19

该研究对8项前瞻性随机试验中接受系列冠状动脉血管内超声检查的患者进行事后患者水平分析,比较使用华法林(171例)与未使用华法林(4129例)患者匹配动脉段内斑块体积百分比和钙化指数的系列变化。结果显示华法林治疗与钙化指数年化增长显著更大相关,且为独立关联,但斑块体积百分比年化变化无显著差异。

要点

  • 华法林治疗患者钙化指数年化增长中位数0.03(IQR 0.0-0.08)vs 未治疗者0.02(IQR 0.0-0.06),p<0.001。
  • 倾向加权调整后斑块体积百分比年化变化华法林组0.33±0.05% vs 非华法林组0.25±0.05%,p=0.17,无显著差异。
  • 多变量模型中华法林与钙化指数增加独立相关(OR 1.16,95%CI 1.05-1.28,p=0.003)。

核心结论

  • 华法林治疗与冠状动脉粥样硬化斑块钙化进展相关,且独立于斑块体积变化;这些变化对斑块稳定性和心血管结局的影响需进一步研究。

研究设计与样本

  • 对8项前瞻性随机试验的事后患者水平分析,使用系列冠状动脉血管内超声检查,比较匹配动脉段在华法林治疗(n=171)与未治疗(n=4,129)患者中18至24个月期间的斑块体积百分比和钙化指数变化。

诊断标准与关键数值

  • 斑块体积百分比总体增加0.41±0.07%(与基线比较p=0.001)。
  • 钙化指数中位数总体增加0.04(IQR 0.00-0.11;与基线比较p<0.001)。
  • 倾向加权调整后,华法林组斑块体积百分比年化变化0.33±0.05% vs 非华法林组0.25±0.05%,p=0.17,无显著差异。
  • 华法林组钙化指数年化增长中位数0.03(IQR 0.0-0.08)vs 非华法林组0.02(IQR 0.0-0.06),p<0.001,华法林组显著更大。
  • 1:1匹配 cohort(每组n=164)敏感性分析中,华法林组钙化指数年化变化亦显著大于非华法林组。

局限性

  • 这些变化对斑块稳定性和心血管结局的影响需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study compared serial changes in coronary percent atheroma volume (PAV) and calcium index (CaI) in patients with coronary artery disease who were treated with and without warfarin.

BACKGROUND: Warfarin blocks the synthesis and activity of matrix Gla protein, a vitamin K-dependent inhibitor of arterial calcification. The longitudinal impact of warfarin on serial coronary artery calcification in vivo in humans is unknown.

METHODS: In a post hoc patient-level analysis of 8 prospective randomized trials using serial coronary intravascular ultrasound examinations, this study compared changes in PAV and CaI in matched arterial segments in patients with coronary artery disease who were treated with (n = 171) and without (n = 4,129) warfarin during an 18- to 24-month period.

RESULTS: Patients (mean age 57.9 ± 9.2 years; male 73%; prior and concomitant 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin) use, 73% and 97%, respectively) demonstrated overall increases in PAV of 0.41 ± 0.07% (p = 0.001 compared with baseline) and in CaI (median) of 0.04 (interquartile range [IQR]: 0.00 to 0.11; p < 0.001 compared with baseline). Following propensity-weighted adjustment for clinical trial and a range of clinical, ultrasonic, and laboratory parameters, there was no significant difference in the annualized change in PAV in the presence and absence of warfarin treatment (0.33 ± 0.05% vs. 0.25 ± 0.05%; p = 0.17). A significantly greater annualized increase in CaI was observed in warfarin-treated compared with non-warfarin-treated patients (median 0.03; IQR: 0.0 to 0.08 vs. median 0.02; IQR: 0.0 to 0.06; p < 0.001). In a sensitivity analysis evaluating a 1:1 matched cohort (n = 164 per group), significantly greater annualized changes in CaI were also observed in warfarin-treated compared with non-warfarin-treated patients. In a multivariate model, warfarin was independently associated with an increasing CaI (odds ratio: 1.16; 95% confidence interval: 1.05 to 1.28; p = 0.003).

CONCLUSIONS: Warfarin therapy is associated with progressive coronary atheroma calcification independent of changes in atheroma volume. The impact of these changes on plaque stability and cardiovascular outcomes requires further investigation.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Andrews J, Psaltis PJ, Bayturan O, et al. Warfarin Use Is Associated With Progressive Coronary Arterial Calcification: Insights From Serial Intravascular Ultrasound. JACC Cardiovasc Imaging. 2017. PMID: 28734922. doi:10.1016/j.jcmg.2017.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。